Predictive Biopharmaceutics and Pharmacokinetics: Modeling and Simulation

Predictive Biopharmaceutics and Pharmacokinetics: Modeling and Simulation

Publication: Developing solid oral dosage forms : pharmaceutical theory & practice
Software: GastroPlus®

Scientists have made great discoveries concerning human physiology and gained tremendous knowledge during drug development efforts.

Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications.

Publication: Regul Toxicol Pharmacol
Software: GastroPlus®

Physiologically based kinetic (PBK) models are used widely throughout a number of working sectors, including academia and industry, to provide insight into the dosimetry related to observed adverse...

Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation

Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation

Publication: Int J Pharm
Software: GastroPlus®

The growing interest in the inhalable pharmaceutical products requires advanced approaches to safe and fast product development, such as in silico tools that can be used...

Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers

Abstract B083: Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor, LY3039478, in patients with advanced cancer and healthy volunteers

Division: PBPK

Background: LY3039478 is an oral Notch inhibitor that prevents release of the Notch Intracellular Domain (NICD) by inhibiting proteolytic activity of the gamma (γ)-secretase complex.

Industry’s View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization.

Industry’s View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization.

Publication: J Pharm Sci
Software: GastroPlus®

This article intends to summarize the current views of the IQ Consortium Dissolution Working Group, which comprises various industry companies, on the roles of dissolution testing throughout...

Population Pharmacokinetics (PK) and Exposure-Efficacy Analyses of Nivolumab in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Population Pharmacokinetics (PK) and Exposure-Efficacy Analyses of Nivolumab in Subjects with Advanced Hepatocellular Carcinoma (HCC)

Conference: ACoP

Nivolumab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that selectively binds to the programmed death-1 (PD-1) membrane receptor. PD-1 is a negative regulatory molecule expressed...

Population Pharmacokinetics and Exposure-Response Analyses for Abatacept in Juvenile Idiopathic Arthritis

Population Pharmacokinetics and Exposure-Response Analyses for Abatacept in Juvenile Idiopathic Arthritis

Conference: ACoP

Polyarticular-course juvenile idiopathic arthritis (pJIA) is the most common chronic rheumatic disorder in children and one of the leading causes of childhood-acquired disability. Treatment with biologic...

Ceftolozane/Tazobactam Dose Selection for Pediatric Patients (Birth to <18 years)

Ceftolozane/Tazobactam Dose Selection for Pediatric Patients (Birth to <18 years)

Conference: ACoP

Ceftolozane/tazobactam is a combination of the novel cephalosporin, ceftolozane, and the beta-lactamase inhibitor, tazobactam. It is approved for the treatment of complicated urinary tract infections (cUTI)...

Prospective Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Modeling

Prospective Liver Safety Comparison of Two Treatments for Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Using Quantitative Systems Toxicology Modeling

Conference: ACoP

The main objective of this research was to prospectively compare the potential for lixivaptan to cause liver toxicity to a comparator drug in the same class, tolvaptan, which has produced off-target liver signals in clinical trials.

The solubility-permeability trade-off of progesterone with cyclodextrins under physiological conditions: Experimental observations and computer simulations

The solubility-permeability trade-off of progesterone with cyclodextrins under physiological conditions: Experimental observations and computer simulations

Authors: Sun L, Zhang B, Sun J
Publication: J Pharm Sci
Software: GastroPlus®

This study intended to evaluate the effect of cyclodextrins on the apparent solubility and permeability of lipophilic drugs under physiological conditions and establish in silico model to choose...

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects

Pharmacokinetics of Tedizolid in Obese and Nonobese Subjects

Publication: J Clin Pharmacol

Obesity, defined as body mass index (BMI) 30 kg/m2, is a growing problem worldwide; the prevalence is 38% in the US adult population.

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm

Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm

Publication: Eur J Clin Pharmacol
Division: PBPK

Despite an improved understanding of the molecular mechanisms of nociception, existing analgesic drugs remain limited in terms of efficacy in chronic conditions, such as neuropathic pain.